Table 2.
Patient Treatment and Prophylactic Anticoagulation Therapy During Hospital Course
| Total COVID Patients (n=25) | Unfavorable Course (n=16) | Favorable Course (n=9) | P value | |
|---|---|---|---|---|
| Medication/Treatment | ||||
| Antiviral medication | ||||
| Remdesivir | 21 (84) | 14 (88) | 7 (78) | 0.524 |
| Glucocorticoid | ||||
| Dexamethasone | 23 (92) | 16 (100) | 7 (78) | 0.120 |
| Antibiotics | 20 (80) | 13 (81) | 7 (78) | 0.835 |
| Anticoagulants | ||||
| Lovenox | 14 (56) | 8 (50) | 6 (67) | 0.420 |
| Heparin | ||||
| SQ | 8 (32) | 4 (25) | 4 (44) | 0.317 |
| IV | 2 (8) | 1 (6) | 1 (11) | 0.667 |
| Quality of Insurance | ||||
| Commercial Payer | 17 (68) | 10 (63) | 7 (78) | 0.432 |
| Government Payer | 8 (32) | 6 (37) | 2 (22) | 0.432 |
Note: Data is presented as n, %.
Abbreviations: SQ, subcutaneous; IV, intravenous.